Avalyn Pharma Inc. (AVLN)
| Market Cap | 1.15B |
| Revenue (ttm) | n/a |
| Net Income | -103.31M |
| EPS | -12.34 |
| Shares Out | 44.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,768 |
| Open | 25.72 |
| Previous Close | 25.72 |
| Day's Range | 19.14 - 33.41 |
| 52-Week Range | 24.14 - 40.17 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 61.80 (+138.52%) |
| Est. Earnings | Nov 25, 2026 |
About AVLN
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for AVLN stock is "Strong Buy." The 12-month stock price target is $61.8, which is an increase of 138.52% from the latest price.
News
Avalyn Pharma initiated with an Outperform at Raymond James
Raymond James analyst Tiago Fauth initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $60 price target Avalyn is developing inhaled formulations of the two most clinically validat...
Avalyn Pharma announces published results from Phase 1 trials of AP02
Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunteers and patients with IPF. Topline data from the…
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile
Results validate Avalyn's approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treat...
Avalyn Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on inhaled therapies for pulmonary fibrosis, the company leverages a patented nebulizer and strong IP to address major unmet needs in a large market. Lead candidates show improved tolerability and efficacy, with pivotal data expected next year and a robust pipeline advancing.
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, ra...
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potentia...
Avalyn Pharma Slides: Corporate presentation
Avalyn Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into cli...
Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an Overweight rating on the shares.
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie...
Avalyn Pharma Quarterly report: Q2 2026
Avalyn Pharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Avalyn Pharma Earnings release: Q2 2026
Avalyn Pharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Avalyn Pharma completes target enrollment in MIST trial
Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with progressive pulmonary fibrosis. Additional patients…
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Avalyn Pharma Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing inhaled therapies for pulmonary fibrosis, aiming to improve tolerability and efficacy over current oral treatments. Key programs are in late-stage clinical trials, with strong long-term data and a robust financial position to support further development and potential market leadership.
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favor...
Avalyn Pharma Earnings release: Q1 2026
Avalyn Pharma released its Q1 2026 earnings on June 3, 2026, summarizing the period's financial results.
Avalyn Pharma Quarterly report: Q1 2026
Avalyn Pharma has published its Q1 2026 quarterly earnings report on June 3, 2026.
Avalyn to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
Avalyn Pharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $51 price target Avalyn has “a strong respiratory pipeline” and the characteristics to...
Avalyn Pharma initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Avalyn Pharma (AVLN) with an Overweight rating and $53 price target The company is well positioned to address the “pressing unmet needs” of pulmonary fibrosis…
Avalyn Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target The firm has “high conviction” in the “multi-blockbuster sales” potential for Aval...
Avalyn Pharma initiated with a Buy at Jefferies
Jefferies initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $52 price target The firm says the company is “solving right problem in pulmonary fibrosis by delivering proven…
Avalyn Pharma initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target